We are developing a portfolio of novel inhalation devices targeted at specific Combination Product opportunities.
Pressurised metered dose inhalers (pMDI) are ubiquitous and are here to stay. We have applied 21st Century engineering techniques to bring the humble press-and-breathe device up to date with a high-clarity, front-mounted, low-cost 200 dose-by-dose counter, and a contemporary design. We are also developing a nasal variant.
Our breath-actuated inhaler (BAI) builds on the features of the press-and-breathe device, but is easier to use; patients simply Open-Inhale-Close.
We have complete control over critical device parameters, including resistance and trigger-flow-rate, enabling us to tune the device to specific therapeutic needs.
Our pre-metered dry powder inhaler (DPI) platform can accommodate multiple formulations, separately or in combination. It has an Open-Inhale-close user-interface and a high-clarity dose-counter.
It has been designed as a delivery device for generic Ellipta® products.
We have deep knowledge of inhalers, garnered from years of developing inhalation products and analysing existing devices. The platforms we have chosen to develop have an established market need. Our scientific approach to development ensures that the needs of all stakeholders are demonstrably met, resulting in simple-to-use, reliable, low-cost inhalers for global regulated markets.